RT Journal Article
SR Electronic
T1 Efficacy and Safety of Hydroxychloroquine and Chloroquine for COVID-19: A Systematic Review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.19.20106906
DO 10.1101/2020.05.19.20106906
A1 Sonal Singh
A1 Thomas J. Moore
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.19.20106906.abstract
AB BACKGROUND Hydroxychloroquine and chloroquine are widely used to treat hospitalized COVID-19 patients primarily based on antiviral activity in in vitro studies. Our objective was to systematically evaluate their efficacy and safety in hospitalized patients with COVID-19.METHODS We systematically reviewed PubMed, ClinicalTrials.gov, and Medrxviv for studies of hydroxychloroquine and chloroquine in COVID-19 hospitalized patients on April 26, 2020. We evaluated the quality of trials and observational studies using the Jadad criteria and Newcastle Ottawa Scale, respectively.RESULTS After a review of 175 citations, we included 5 clinical trials (total of 345 patients), 9 observational studies (n = 2529), and 6 additional studies (n = 775) reporting on the QT interval. Three studies reported treatment benefits including two studies reporting benefit on virologic outcomes, which was statistically significant in one study, and another reported significant improvement on cough symptoms. Three studies reported that treatment was potentially harmful, including an significantly increased risk of mortality in two studies and increased need for respiratory support in another. Eight studies were unable to detect improvements on virologic outcomes (n = 3) or pneumonia or transfer to ICU/death (n = 5). The proportion of participants with critical QTc intervals of ≥ 500 ms or an increase of ≥ 60 ms from baseline ranged from 8.3% to 36% (n = 8). One clinical trial and six observational studies were of good quality. The remaining studies were of poor quality.CONCLUSIONS Our systematic review of reported clinical studies did not identify substantial evidence to support the efficacy of hydroxychloroquine or chloroquine in hospitalized COVID-19 patients and raises questions about potential harm from QT prolongation and increased mortality.Key PointsWe conducted a systematic review of the efficacy and safety of hydroxychloroquine and chloroquine among patients hospitalized with COVID-19 and identified 14 studies reporting on clinical or virologic outcomes and 6 additional studies reporting on the QT interval.We conducted a systematic review of the efficacy and safety of hydroxychloroquine and chloroquine among patients hospitalized with COVID-19 and identified 14 studies reporting on clinical or virologic outcomes and 6 additional studies reporting on the QT interval.Hydroxychloroquine or chloroquine improved virologic outcomes in 2 clinical studies and cough in another study.We conducted a systematic review of the efficacy and safety of hydroxychloroquine and chloroquine among patients hospitalized with COVID-19 and identified 14 studies reporting on clinical or virologic outcomes and 6 additional studies reporting on the QT interval.Hydroxychloroquine or chloroquine improved virologic outcomes in 2 clinical studies and cough in another study.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere were no sources of funding for this paperAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available on request and are attached as appendix